Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 Jul;68(4):262–270. doi: 10.1016/j.curtheres.2007.08.002

Effects of Zileuton on the Development of Autoimmune Myocarditis in an Experimental Rat Model

Ender Odemis 1,*, Sadi Turkay 1, Cemile Koca 2, Halil Kiyici 3, Ahmet Karadag 4, Reyhan Bayrak 5, Emin Mete 4, Ferhat Catal 4, Ramazan Yigitoglu 2
PMCID: PMC3967347  PMID: 24683216

Abstract

Background: Myocarditis is associated with high morbidity and mortality in childhood, but the pathogenesis of this disease is still unclear. Current knowledge indicates that complex immunopathogenic mechanisms are involved. It is understood that leukotrienes play an important role in the inflammation associated with asthma, and recent reports indicate that leukotrienes participate in immune processes and in autoimmunity.

Objective: The aim of this study was to assess the role of leukotriene synthesis in the development of myocardial inflammation and necrosis during myocarditis.

Methods: The effect of zileuton, a leukotriene synthesis inhibitor, was assessed in an experimental model of autoimmune myocarditis in rats. Healthy adult (10-week-old) male Wistar albino rats were randomly divided into 3 groups. Groups A and B received injections of 1.0 mg porcine cardiac myosin to induce autoimmune myocarditis and group C (the control group) received phosphate-buffered saline. Group B also received zileuton by oral gavage at 100 mg/kg · d−1. Myocardial inflammation was assessed biochemically via serum concentrations of creatine kinase MB subunit (CK-MB) and troponin T. Cardiac tissue was assessed macroscopically (0 = no inflammation; 1 = a small discolored focus; 2 = diffuse discolored areas covering less than half of the cardiac surface; 3 = diffuse discolored areas covering more than half of the cardiac surface) and microscopically (0 = no inflammation; 1 = ⪯5% infiltration; 2 = 5% to <10% infiltration; 3 = 10% to < 20% infiltration; 4 = >20% infiltration).

Results: Twenty-four rats were divided equally into 3 groups. All rats survived the duration of the study. After 21 days, all rats were euthanized. No significant differences were found between groups A and B in terms of serum concentrations of CK-MB or troponin T. The microscopic pathology score was significantly lower in group B (myosin + zileuton) than in group A (myosin only) (0.12 [0.35] vs 1.25 [1.03]; P = 0.023). The microscopic pathology score was significantly higher in group A than in group C (1.25 [1.03] vs 0; P < 0.01), but the difference between groups B and C was not statistically significant. The macroscopic pathology score was significantly higher in group A than in group B (1.37 [0.91] vs 0.37 [0.51]; P = 0.029). The macroscopic pathology score was significantly higher in group A than in group C (1.37 [0.91] vs 0; P < 0.01). There was no significant difference in macroscopic scores between groups B and C (0.37 [0.51] vs 0).

Conclusions: In this study of the effects of zileuton in an experimental rat model of autoimmune myocarditis, no significant differences were found in the serum concentrations of the biochemical markers in the 2 groups administered myosin. However, lower macroscopic and microscopic inflammation scores in the zileuton-treated group (group B) compared with the group administered only myosin (group A) suggest that zileuton, a leukotriene-synthesis inhibitor, may suppress the development of experimental autoimmune myocarditis in rats.

Key words: autoimmunity, myocarditis, rats, leukotrienes, zileuton

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

References

  • 1.Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004;180:110–112. doi: 10.5694/j.1326-5377.2004.tb05830.x. [DOI] [PubMed] [Google Scholar]
  • 2.Magnani JW, Dec GW. Myocarditis: Current trends in diagnosis and treatment. Circulation. 2006;113:876–890. doi: 10.1161/CIRCULATIONAHA.105.584532. [DOI] [PubMed] [Google Scholar]
  • 3.Kodama M, Matsumoto Y, Fujiwara M. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990;57:250–262. doi: 10.1016/0090-1229(90)90039-s. [DOI] [PubMed] [Google Scholar]
  • 4.Shioji K, Kishimoto C, Nakayama Y, Sasayama S. Strain difference in rats with experimental giant cell myocarditis. Jpn Circ J. 2000;64:283–286. doi: 10.1253/jcj.64.283. [DOI] [PubMed] [Google Scholar]
  • 5.Huber SA. Autoimmunity in myocarditis: Relevance of animal models. Clin Immunol Immunopathol. 1997;83:93–102. doi: 10.1006/clin.1997.4342. [DOI] [PubMed] [Google Scholar]
  • 6.Hedqvist P, Gautam N, Lindbom L. Interactions between leukotrienes and other inflammatory mediators/modulators in the microvasculature. Am J Respir Crit Care Med. 2000;161:S117–S119. doi: 10.1164/ajrccm.161.supplement_1.ltta-23. [DOI] [PubMed] [Google Scholar]
  • 7.Sharma JN, Mohammed LA. The role of leukotrienes in the pathophysiology of inflammatory disorders: Is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology. 2006;14:10–16. doi: 10.1007/s10787-006-1496-6. [DOI] [PubMed] [Google Scholar]
  • 8.Association for Assessment and Accreditation of International Laboratory Animal Care . Institute of Laboratory Animals Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. National Academy Press; Washington, DC: 1996. [Google Scholar]
  • 9.Milenkovic M, Vucicevic D, Milosavljevic P. Suppression of experimental autoimmune myocarditis by sodium fusidate (fusidin) Pharmacol Res. 2005;52:491–496. doi: 10.1016/j.phrs.2005.08.001. [DOI] [PubMed] [Google Scholar]
  • 10.Burian J, Buser P, Eriksson U. Myocarditis: The immunologist's view on pathogenesis and treatment. Swiss Med Wkly. 2005;135:359–364. doi: 10.4414/smw.2005.10940. [DOI] [PubMed] [Google Scholar]
  • 11.Ayach B, Fuse K, Martino T, Liu P. Dissecting mechanisms of innate and acquired immunity in myocarditis. Curr Opin Cardiol. 2003;18:175–181. doi: 10.1097/00001573-200305000-00001. [DOI] [PubMed] [Google Scholar]
  • 12.Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myocarditis and dilated cardiomyopathy: Mechanisms, manifestations, and management. Postgrad Med J. 2001;77:4–10. doi: 10.1136/pmj.77.903.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/c mice: Evidence for autoimmunity to myocyte antigens. Am JPathol. 1984;116:21–29. [PMC free article] [PubMed] [Google Scholar]
  • 14.Jozefowski S, Biedron R, Bobek M, Marcinkiewicz J. Leukotrienes modulate cytokine release from dendritic cells. Immunology. 2005;116:418–428. doi: 10.1111/j.1365-2567.2005.02241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: Underappreciated mediators of innate immune responses. J Immunol. 2005;174:589–594. doi: 10.4049/jimmunol.174.2.589. [DOI] [PubMed] [Google Scholar]
  • 16.Lauer B, Niederau C, Kuhl U. Cardiac troponin T in patients with clinically suspected myocarditis. JAm Coil Cardiol. 1997;30:1354–1359. doi: 10.1016/s0735-1097(97)00317-3. [DOI] [PubMed] [Google Scholar]
  • 17.Yopp AC, Randolph GJ, Bromberg JS. Leukotrienes, sphingolipids, and leukocyte trafficking. J Immunol. 2003;171:5–10. doi: 10.4049/jimmunol.171.1.5. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES